Auriga

According to a research report released today, Auriga is slicing its estimates for PMC-Sierra (NASDAQ: PMCS) as the company's 1Q12 guidance fell short of estimates. “A weak guidance was partially offset by a strong 1.2+ Book-to-Bill, a large decline in legacy overhang and a commitment to reduce...

According to a research report released today, Auriga has increased Astronics Corporation's (NASDAQ: ATRO) PT from $35 to $38 after the company reported an incredible 4Q. “Astronics reported a solid fourth-quarter, with upside stemming from better-than-expected demand of its cabin electronics...

In a research report published earlier today, Auriga increased Glove Specialty Metals' (NASDAQ: GSM) PT from $17 to $20 and maintains its Buy rating. According to Auriga, “The combination of end markets continuing to improve and the integration of the Alden Resources (coal assets) acquisition...

In a research report published earlier today, Auriga increased First Solar Inc.'s (NASDAQ: FSLR) PT from $41 to $53 and maintains its Buy rating. According to Auriga, “Our EPS estimates have a note of conservatism, and it is more likely they move up than down. Should First Solar fall short or...

According to a recent research report, Auriga is increasing DepoMed Inc.'s (NASDAQ: DEPO) PT from $7 to $8 in hopes that Janumet's XR commercial launch will boost royalty income in 2012. Auriga commented in the report, “Janumet XR could bring annual royalty income in the range of $10-$20 million...

Auriga has raised the price target on DepoMed (NASDAQ: DEPO) from $7 to $8 and maintains its Buy rating.

Auriga reiterates its Buy rating on Cavium (NASDAQ: CAVM) and raised its price target to $39 from $37 a share as strong growth will likely resume in 2Q12. Auriga says, "the company indicated that it expects strong sequential growth (10%+ in our view) to resume in 2Q12 after soft 1Q12 guidance....

Auriga has raised the price target on Cavium (NASDAQ: CAVM) from $37 to $41 and maintains its Buy rating.

Auriga lowers its rating on Broadcom (NASDAQ: BRCM) to Hold from Buy on valuation but raises its price target to $37 from $35 on the consensus beat the company delivered for the quarter on both print and guide. Auriga notes, "While near-term trends look encouraging as China service provider...

Auriga reiterates its Buy rating on Seagate (NASDAQ: STX) and raises its price to $38 from $32 as the company beats twice-increased estimates and guides massive upside for next quarter. Auriga comments, "Seagate beat December estimates and massively increased forward guidance. With strong...

Auriga maintains its Buy rating on Myriad Genetics (NASDAQ: MYGN) and raises its price target to $28 from $24 a share on earnings beat delivered by the company for the quarter. Auriga comments, "Myriad Genetics (MYGN, Buy) reported F2Q12 revenue of $122.8MM, well ahead of our $115.6MM estimate...

Auriga has raised the price target on Seagate Technology (NASDAQ: STX) from $32 to $38 and maintains its Buy rating.

Auriga has downgraded Broadcom (NASDAQ: BRCM) from Buy to Hold and has raised the price target from $35 to $37.